Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (Q28202504)

2

Brian G Feagan

0 references

Jean-Frédéric Colombel

6

Jean Frederic Colombel

0 references

Stephen B Hanauer

1

Stephen B Hanauer

0 references

Gary R Lichtenstein

3

Gary R Lichtenstein

0 references

Daniel Rachmilewitz

7

Daniel Rachmilewitz

0 references

Douglas C Wolf

8

Douglas C Wolf

0 references

Weihang Bao

10

Weihang Bao

0 references

author name string

Lloyd F Mayer

4

0 references

S Schreiber

5

0 references

Allan Olson

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

9

0 references

language of work or name

English

0 references

publication date

4 May 2002

0 references

published in

The Lancet

0 references

volume

359

0 references

issue

9317

0 references

page(s)

1541-9

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Methotrexate for the Treatment of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Tumour necrosis factor alpha in stool as a marker of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Infliximab in Crohn's disease: first anniversary clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Mechanisms in failure of infliximab for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Cancer risk in patients with inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

Lymphoma in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908512-4

7 January 2021

10.1016/S0140-6736(02)08512-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1523317

1523317

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference